Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.71 |
| ▸ | HRH1 | P35367 | 2/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22813547 | 0.87 | SCN5A (0.71) | HRH3HRH1SCN5ASLC6A4SLC6A3 | |
| SCHEMBL6984190 | 0.85 | SCN5A (0.74) | HRH3HRH1SCN5ASLC6A4SLC6A3 | |
| SCHEMBL492156 | 0.84 | HRH3 (0.97) | HRH3SLC6A2HRH1SCN5ASLC6A4 | |
| Pitolisant SCHEMBL117648 | 0.83 | HRH3 (1.00) | HRH3SLC6A2HRH1SCN5ASLC6A4 | |
| SCHEMBL2451795 | 0.83 | HRH1 (0.74) | HRH3SLC6A2HRH1SCN5ASLC6A4 | |
| SCHEMBL491655 | 0.83 | HRH3 (1.00) | HRH3SLC6A2HRH1SCN5ASLC6A4 | |
| SCHEMBL23731966 | 0.82 | SCN5A (0.66) | HRH3HRH1SCN5ASLC6A4SLC6A3 | |
| SCHEMBL8114961 | 0.82 | HRH3 (0.73) | HRH3SCN5AMEN1LMNAHTT | |
| Pitolisant SCHEMBL4591893 | 0.82 | HRH3 (1.00) | HRH3SLC6A2HRH1SCN5ASLC6A4 | |
| SCHEMBL2451767 | 0.80 | HRH3 (0.61) | HRH3SLC6A2HRH1SCN5ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | claimed |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | BIOPROJET (FR) | 2008-07-31 | — | — | US | claimed |
| EP-1874747-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2008-01-09 | — | — | EP | claimed |
| WO-2006117611-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2006-11-09 | — | — | WO | claimed |
| EP-1717233-A1 | Histamine H3-receptor ligands and their therapeutic application | BIOPROJET (FR) | 2006-11-02 | — | — | EP | claimed |
| US-8106041-B2 | Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | disclosed |
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | disclosed |
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | disclosed |
| EP-1641461-B1 | COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H<SB>3</SB> AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS | BIOPROJET SOC CIV (FR) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312367-A1 | COMBINATION OF MODAFINIL AND AN ANTAGONIST OR INVERSE AGONIST OF THE H3 RECEPTOR | BIOPROJET (FR) | 2009-12-17 | — | — | US | disclosed |
| EP-2043624-A2 | COMBINATION OF MODAFINIL AND AN ANTAGONIST OR INVERSE AGONIST OF THE H3 RECEPTOR | BIOPROJET (FR) | 2009-04-08 | — | — | EP | disclosed |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | BIOPROJET (FR) | 2008-07-31 | — | — | US | disclosed |
| WO-2008009866-A2 | COMBINATION OF MODAFINIL AND AN ANTAGONIST OR INVERSE AGONIST OF THE H3 RECEPTOR | BIOPROJET (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1874747-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117611-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717233-A1 | Histamine H3-receptor ligands and their therapeutic application | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2006-09-21 | — | — | US | disclosed |
| EP-1641461-A1 | COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H&lt;SB&gt;3&lt;/SB&gt;AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS | BIOPROJET (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000315-A1 | COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H3 AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS | BIOPROJET (FR) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | HRH3, HRH4, HRH2 | HRH3 1/4885SLC6A2 215/4885HRH1 4/4885 |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | HRH3, HRH4, HRH1 | HRH3 1/4885SLC6A2 576/4885HRH1 3/4885 |
| US-20090312367-A1 | COMBINATION OF MODAFINIL AND AN ANTAGONIST OR INVERSE AGONIST OF THE H3 RECEPTOR | HRH3, HCRTR2, HCRTR1 | HRH3 1/4885SLC6A2 259/4885HRH1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.